Glioma Pathophysiology: Insights Emerging from Proteomics

Ruth F. Deighton, Richard McGregor, Jocelyn Kemp, James McCulloch, Ian R. Whittle

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

Proteomics is increasingly employed in both neurological and oncological research to provide insight into the molecular basis of disease but rarely has a coherent, novel pathophysiological insight emerged. Gliomas account for > 50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common. In glioma, the application of proteomic technology has identified altered protein expression but without consistency of these alterations or their biological significance being established. A systematic review of multiple independent proteomic analyses of glioma has demonstrated alterations of 99 different proteins. Importantly 10 of the 99 proteins found differentially expressed in glioma [PHB, Hsp20, serum albumin, epidermal growth factor receptor (EGFR), EA-15, RhoGDI, APOA1, GFAP, HSP70, PDIA3] were identified in multiple publications. An assessment of protein-protein interactions between these proteins compiled using novel web-based technology, revealed a robust and cohesive network for glioblastoma. The protein network discovered (containing TP53 and RB1 at its core) compliments recent findings in genomic studies of malignant glioma. The novel perspective provided by network analysis indicates that the potential of this technology to explore crucial aspects of glioma pathophysiology can now be realized but only if the conceptual and technical limitations highlighted in this review are addressed.

Original languageEnglish
Pages (from-to)691-703
Number of pages13
JournalBrain Pathology
Issue number4
Publication statusPublished - Jul 2010


Dive into the research topics of 'Glioma Pathophysiology: Insights Emerging from Proteomics'. Together they form a unique fingerprint.

Cite this